Technology & Products

The Cytovia team and its advisors apply a translational approach to the latest development in immunology research. Our focus is on the targeted activation of Natural Killer (NK) cells through a variety of approaches - including cell therapy and multispecific antibodies - to improve the clinical performance of immunotherapy in cancer and infectious diseases.

Cytovia is developing NKp46 multifunctional engagers with the potential for better disease control without hurting the healthy cells.


Subscribe Form

  • Facebook
  • Twitter
  • LinkedIn
  • YouTube